[WSJ] Will Gilead’s Hepatitis C Drug Bust State Budgets?
Will the cost of new hepatitis C treatments bust state budgets? A new analysis… Read More
Will the cost of new hepatitis C treatments bust state budgets? A new analysis… Read More
“As longtime health-care advocate John Rother sees it, the Sovaldi issue is… Read More
Eighty-two percent in a new poll say the cost of a $1,000-a-pill medicine… Read More
Two high-ranking senators have lent their voices to the chorus demanding to… Read More
By: Brett Norman A bipartisan pair of senators is asking the pharmaceutical… Read More
Gilead Sciences Inc. has been asked by two U.S. senators to explain how it… Read More
On Friday, July 11, AEI is hosting a session entitled “How will we pay for… Read More
The debate over the price of specialty drugs is intensifying and could well be… Read More
Costs to New Yorkers for One Drug Is 4 Times Entire Higher Education Spending… Read More
Sovaldi, the new drug to treat and cure Hepatitis C has certainly caused quite… Read More
A cure for hepatitis C is within reach for 170 million people around the world… Read More
Eyeing a $168-million annual price tag for two costly new hepatitis C drugs,… Read More